Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity

Ciro Zanca, Genaro R. Villa, Jorge A. Benitez, Amy Haseley Thorne, Tomoyuki Koga, Matteo D’Antonio, Shiro Ikegami, Jianhui Ma, Antonia D. Boyer, Afsheen Banisadr, Nathan M. Jameson, Alison D. Parisian, Olesja V. Eliseeva, Gabriela F. Barnabe, Feng Liu, Sihan Wu, Huijun Yang, Jill Wykosky, Kelly A. Frazer, Vladislav Verkhusha & 8 others Maria G. Isaguliants, William A. Weiss, Timothy C. Gahman, Andrew K. Shiau, Clark C. Chen, Paul S. Mischel, Webster K. Cavenee, Frank B. Furnari

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In glioblastoma (GBM), heterogeneous expression of amplified and mutated epidermal growth factor receptor (EGFR) presents a substantial challenge for the effective use of EGFR-directed therapeutics. Here we demonstrate that heterogeneous expression of the wild-type receptor and its constitutively active mutant form, EGFRvIII, limits sensitivity to these therapies through an interclonal communication mechanism mediated by interleukin-6 (IL-6) cytokine secreted from EGFRvIII-positive tumor cells. IL-6 activates a NF-κB signaling axis in a paracrine and autocrine manner, leading to bromodomain protein 4 (BRD4)-dependent expression of the prosurvival protein survivin (BIRC5) and attenuation of sensitivity to EGFR tyrosine kinase inhibitors (TKIs). NF-κB and survivin are coordinately up-regulated in GBM patient tumors, and functional inhibition of either protein or BRD4 in in vitro and in vivo models restores sensitivity to EGFR TKIs. These results provide a rationale for improving anti-EGFR therapeutic efficacy through pharmacological uncoupling of a convergence point of NF-κB-mediated survival that is leveraged by an interclonal circuitry mechanism established by intratumoral mutational heterogeneity.

Original languageEnglish (US)
Pages (from-to)1212-1227
Number of pages16
JournalGenes and Development
Volume31
Issue number12
DOIs
StatePublished - Jun 15 2017

Fingerprint

Glioblastoma
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Interleukin-6
Proteins
Neoplasms
Therapeutics
Communication
Pharmacology
Cytokines
Survival
epidermal growth factor receptor VIII

Keywords

  • EGFR
  • Glioblastoma
  • IL-6
  • NF-κB
  • Survivin
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Zanca, C., Villa, G. R., Benitez, J. A., Thorne, A. H., Koga, T., D’Antonio, M., ... Furnari, F. B. (2017). Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes and Development, 31(12), 1212-1227. https://doi.org/10.1101/gad.300079.117

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. / Zanca, Ciro; Villa, Genaro R.; Benitez, Jorge A.; Thorne, Amy Haseley; Koga, Tomoyuki; D’Antonio, Matteo; Ikegami, Shiro; Ma, Jianhui; Boyer, Antonia D.; Banisadr, Afsheen; Jameson, Nathan M.; Parisian, Alison D.; Eliseeva, Olesja V.; Barnabe, Gabriela F.; Liu, Feng; Wu, Sihan; Yang, Huijun; Wykosky, Jill; Frazer, Kelly A.; Verkhusha, Vladislav; Isaguliants, Maria G.; Weiss, William A.; Gahman, Timothy C.; Shiau, Andrew K.; Chen, Clark C.; Mischel, Paul S.; Cavenee, Webster K.; Furnari, Frank B.

In: Genes and Development, Vol. 31, No. 12, 15.06.2017, p. 1212-1227.

Research output: Contribution to journalArticle

Zanca, C, Villa, GR, Benitez, JA, Thorne, AH, Koga, T, D’Antonio, M, Ikegami, S, Ma, J, Boyer, AD, Banisadr, A, Jameson, NM, Parisian, AD, Eliseeva, OV, Barnabe, GF, Liu, F, Wu, S, Yang, H, Wykosky, J, Frazer, KA, Verkhusha, V, Isaguliants, MG, Weiss, WA, Gahman, TC, Shiau, AK, Chen, CC, Mischel, PS, Cavenee, WK & Furnari, FB 2017, 'Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity', Genes and Development, vol. 31, no. 12, pp. 1212-1227. https://doi.org/10.1101/gad.300079.117
Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D’Antonio M et al. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes and Development. 2017 Jun 15;31(12):1212-1227. https://doi.org/10.1101/gad.300079.117
Zanca, Ciro ; Villa, Genaro R. ; Benitez, Jorge A. ; Thorne, Amy Haseley ; Koga, Tomoyuki ; D’Antonio, Matteo ; Ikegami, Shiro ; Ma, Jianhui ; Boyer, Antonia D. ; Banisadr, Afsheen ; Jameson, Nathan M. ; Parisian, Alison D. ; Eliseeva, Olesja V. ; Barnabe, Gabriela F. ; Liu, Feng ; Wu, Sihan ; Yang, Huijun ; Wykosky, Jill ; Frazer, Kelly A. ; Verkhusha, Vladislav ; Isaguliants, Maria G. ; Weiss, William A. ; Gahman, Timothy C. ; Shiau, Andrew K. ; Chen, Clark C. ; Mischel, Paul S. ; Cavenee, Webster K. ; Furnari, Frank B. / Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. In: Genes and Development. 2017 ; Vol. 31, No. 12. pp. 1212-1227.
@article{b7a137921b514b3c9ff3cbff52732436,
title = "Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity",
abstract = "In glioblastoma (GBM), heterogeneous expression of amplified and mutated epidermal growth factor receptor (EGFR) presents a substantial challenge for the effective use of EGFR-directed therapeutics. Here we demonstrate that heterogeneous expression of the wild-type receptor and its constitutively active mutant form, EGFRvIII, limits sensitivity to these therapies through an interclonal communication mechanism mediated by interleukin-6 (IL-6) cytokine secreted from EGFRvIII-positive tumor cells. IL-6 activates a NF-κB signaling axis in a paracrine and autocrine manner, leading to bromodomain protein 4 (BRD4)-dependent expression of the prosurvival protein survivin (BIRC5) and attenuation of sensitivity to EGFR tyrosine kinase inhibitors (TKIs). NF-κB and survivin are coordinately up-regulated in GBM patient tumors, and functional inhibition of either protein or BRD4 in in vitro and in vivo models restores sensitivity to EGFR TKIs. These results provide a rationale for improving anti-EGFR therapeutic efficacy through pharmacological uncoupling of a convergence point of NF-κB-mediated survival that is leveraged by an interclonal circuitry mechanism established by intratumoral mutational heterogeneity.",
keywords = "EGFR, Glioblastoma, IL-6, NF-κB, Survivin, Tumor heterogeneity",
author = "Ciro Zanca and Villa, {Genaro R.} and Benitez, {Jorge A.} and Thorne, {Amy Haseley} and Tomoyuki Koga and Matteo D’Antonio and Shiro Ikegami and Jianhui Ma and Boyer, {Antonia D.} and Afsheen Banisadr and Jameson, {Nathan M.} and Parisian, {Alison D.} and Eliseeva, {Olesja V.} and Barnabe, {Gabriela F.} and Feng Liu and Sihan Wu and Huijun Yang and Jill Wykosky and Frazer, {Kelly A.} and Vladislav Verkhusha and Isaguliants, {Maria G.} and Weiss, {William A.} and Gahman, {Timothy C.} and Shiau, {Andrew K.} and Chen, {Clark C.} and Mischel, {Paul S.} and Cavenee, {Webster K.} and Furnari, {Frank B.}",
year = "2017",
month = "6",
day = "15",
doi = "10.1101/gad.300079.117",
language = "English (US)",
volume = "31",
pages = "1212--1227",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "12",

}

TY - JOUR

T1 - Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity

AU - Zanca, Ciro

AU - Villa, Genaro R.

AU - Benitez, Jorge A.

AU - Thorne, Amy Haseley

AU - Koga, Tomoyuki

AU - D’Antonio, Matteo

AU - Ikegami, Shiro

AU - Ma, Jianhui

AU - Boyer, Antonia D.

AU - Banisadr, Afsheen

AU - Jameson, Nathan M.

AU - Parisian, Alison D.

AU - Eliseeva, Olesja V.

AU - Barnabe, Gabriela F.

AU - Liu, Feng

AU - Wu, Sihan

AU - Yang, Huijun

AU - Wykosky, Jill

AU - Frazer, Kelly A.

AU - Verkhusha, Vladislav

AU - Isaguliants, Maria G.

AU - Weiss, William A.

AU - Gahman, Timothy C.

AU - Shiau, Andrew K.

AU - Chen, Clark C.

AU - Mischel, Paul S.

AU - Cavenee, Webster K.

AU - Furnari, Frank B.

PY - 2017/6/15

Y1 - 2017/6/15

N2 - In glioblastoma (GBM), heterogeneous expression of amplified and mutated epidermal growth factor receptor (EGFR) presents a substantial challenge for the effective use of EGFR-directed therapeutics. Here we demonstrate that heterogeneous expression of the wild-type receptor and its constitutively active mutant form, EGFRvIII, limits sensitivity to these therapies through an interclonal communication mechanism mediated by interleukin-6 (IL-6) cytokine secreted from EGFRvIII-positive tumor cells. IL-6 activates a NF-κB signaling axis in a paracrine and autocrine manner, leading to bromodomain protein 4 (BRD4)-dependent expression of the prosurvival protein survivin (BIRC5) and attenuation of sensitivity to EGFR tyrosine kinase inhibitors (TKIs). NF-κB and survivin are coordinately up-regulated in GBM patient tumors, and functional inhibition of either protein or BRD4 in in vitro and in vivo models restores sensitivity to EGFR TKIs. These results provide a rationale for improving anti-EGFR therapeutic efficacy through pharmacological uncoupling of a convergence point of NF-κB-mediated survival that is leveraged by an interclonal circuitry mechanism established by intratumoral mutational heterogeneity.

AB - In glioblastoma (GBM), heterogeneous expression of amplified and mutated epidermal growth factor receptor (EGFR) presents a substantial challenge for the effective use of EGFR-directed therapeutics. Here we demonstrate that heterogeneous expression of the wild-type receptor and its constitutively active mutant form, EGFRvIII, limits sensitivity to these therapies through an interclonal communication mechanism mediated by interleukin-6 (IL-6) cytokine secreted from EGFRvIII-positive tumor cells. IL-6 activates a NF-κB signaling axis in a paracrine and autocrine manner, leading to bromodomain protein 4 (BRD4)-dependent expression of the prosurvival protein survivin (BIRC5) and attenuation of sensitivity to EGFR tyrosine kinase inhibitors (TKIs). NF-κB and survivin are coordinately up-regulated in GBM patient tumors, and functional inhibition of either protein or BRD4 in in vitro and in vivo models restores sensitivity to EGFR TKIs. These results provide a rationale for improving anti-EGFR therapeutic efficacy through pharmacological uncoupling of a convergence point of NF-κB-mediated survival that is leveraged by an interclonal circuitry mechanism established by intratumoral mutational heterogeneity.

KW - EGFR

KW - Glioblastoma

KW - IL-6

KW - NF-κB

KW - Survivin

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85027005612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027005612&partnerID=8YFLogxK

U2 - 10.1101/gad.300079.117

DO - 10.1101/gad.300079.117

M3 - Article

VL - 31

SP - 1212

EP - 1227

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 12

ER -